Biologics Litigation and IPRs

To access a recording of this webinar or receive a copy of the slides, please contact [email protected].

As the popularity of biosimilars continues to grow in the United States, biosimilar and biologics manufacturers have begun testing the bounds of the BPCIA statute in district court litigation. In addition, biosimilar manufacturers have also turned to IPR proceedings to challenge patents covering biologic drugs.

Join Fish attorneys Chad Shear and Gwilym Attwell for our next installment of our biologics webinar series. This presentation will focus on recent developments, including:

• Recent district court cases and their impact on the biosimilars industry
• IPRs challenging biologic patents
• Strategies for biologics litigation